TNGX
TNGX
NASDAQ · Biotechnology

Tango Therapeutics Inc

$27.97
-4.32 (-13.38%)
Financial Highlights (FY 2026)
Revenue
79.04M
Net Income
-128,728,625
Gross Margin
Profit Margin
-162.9%
Rev Growth
+35.9%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 30.1% 30.1%
Operating Margin -178.4% -160.6% -20.8% -21.5%
Profit Margin -162.9% -154.7% -27.2% -24.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 79.04M 58.16M 421.41M 456.66M
Gross Profit 127.00M 137.62M
Operating Income -140,997,186 -93,382,491 -87,784,070 -98,156,679
Net Income -128,728,625 -85,257,018 -114,600,480 -110,156,724
Gross Margin 30.1% 30.1%
Operating Margin -178.4% -160.6% -20.8% -21.5%
Profit Margin -162.9% -154.7% -27.2% -24.1%
Rev Growth +35.9% +35.9% +7.1% +20.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 721.39M 673.97M
Total Equity 1.19B 1.15B
D/E Ratio 0.61 0.59
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -138,119,074 -96,558,334 -127,773,532 -138,708,079
Free Cash Flow -89,915,808 -70,983,895